Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), T. Karampitsakos (Athens, Greece), M. Ntassiou (Athens, Greece), E. Avdoula (Athens, Greece), A. Trachalaki (Athens, Greece), K. Antoniou (Athens, Greece), D. Bouros (Athens, Greece). Efficacy of antifibrotics in chronic hypersensitivity pneumonitis. A 3 year real-life observational study. 737

Member's Comments

No comment yet.

Related content which might interest you: Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study Source: ERJ Open Res, 6 (4) 00152-2020; 10.1183/23120541.00152-2020 Year: 2020 Efficacy and safety of sequential three-step empirical therapy for chronic cough: a multi-center clinical study Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials Source: International Congress 2017 – Asthma management Year: 2017 Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Benefits of interferon-αcon-1 (IFN-αcon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 A new treatment algorithm for acute exacerbation of IPF: a retrospective cohort study. Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019 Feasibility of home spirometry in patients with chronic graft-versus-host disease: a prospective observational study Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers Year: 2020 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Efficacy of reslizumab in adults with severe eosinophilic asthma with =3 exacerbations in the previous year: analyses at weeks 16 and 52 of two placebo-controlled phase 3 trials Source: International Congress 2017 – Asthma epidemiology among children and adults: from biomarkers to ACOS Year: 2017 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015